ORLADEYO® (berotralstat) capsules

This list does not imply that the products on this chart are interchangeable or have the same efficacy or safety. Please refer to each product's FDA-approved label and indication for further information.

The prices listed below are average wholesale prices (AWPs) as established and made available to the public by a third-party publisher. The price paid by consumers may be higher or lower than the prices listed below. Information about AWPs of these drugs is being provided to Vermont prescribers pursuant to Vermont law, to give you information about the relative prices of marketed drugs and other drugs in the same therapeutic class.

The prices listed here do not necessarily reflect price per dosage, price per course of treatment, or the cost effectiveness of all the products listed. For simplicity, only the smallest package size available for each product are included.

				AWP			
Product name	Manufacturer	NDC or UPC	Pkg size	Per package	Per unit		
Marketed products							
ORLADEYO 150 MG CAPSULE	BIOCRYST PHARMACEUTICALS	72769-0101-01	28 EA	\$50,839.24	\$1,815.69		
ORLADEYO 110 MG CAPSULE	BIOCRYST PHARMACEUTICALS	72769-0102-01	28 EA	\$50,839.24	\$1,815.69		

Product name	Manufacturer	NDC or UPC				
Other products						
TAKHZYRO 300 MG/2 ML SUBCUTANEOUS SOLUTION	SHIRE US INC.	47783-0644-01	NON-PILL PRODUCT			
HAEGARDA 2000 IU VIAL SUBCUTANEOUS SOLUTION RECONSTITUTED	CSL BEHRING	63833-0828-02	NON-PILL PRODUCT			
HAEGARDA 3000 IU VIAL SUBCUTANEOUS SOLUTION RECONSTITUTED	CSL BEHRING	63833-0829-02	NON-PILL PRODUCT			
CINRYZE 500 UNIT VIAL INTRAVENOUS SOLUTION RECONSTITUTED	VIROPHARMA	42227-0081-05	NON-PILL PRODUCT			
TAKHZYRO 300 MG/2 ML SUBCUTANEOUS SOLUTION PREFILLED SYRINGE	SHIRE US INC.	47783-0646-01	NON-PILL PRODUCT			

Source: Medi-Span, January 3, 2024

ORLADEYO is a trademark of BioCryst Pharmaceuticals, Inc. © 2024 BioCryst Pharmaceuticals, Inc. All rights reserved. US.ORL.01790 1/24